Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310

In a phase 1a trial, one-time CRISPR-Cas9 gene editing with CTX310 was associated with no treatment-related dose-limiting toxic effects and with sustained reductions in ANGPTL3 and atherogenic lipids at 1 year.